Search research articles
Contact Us
Filters
Showing results (61-70 of 107) with videos related to
Page
of 11
Sort By:
Gynecologic Oncology
|
March 15, 2024
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer
Paul Gass, Falk C Thiel, Lothar Häberle, et al.
International Journal of Surgery (London, England)
|
February 24, 2025
Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis
Fabian Trillsch, Bastian Czogalla, Sven Mahner, et al.
Annals of Surgical Oncology
|
March 16, 2021
Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study
Linn Woelber, Mareike Bommert, Philipp Harter, et al.
Gynecologic Oncology
|
February 15, 2019
Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study
Stephan Polterauer, Richard Schwameis, Christoph Grimm, et al.
The Oncologist
|
June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
Felicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
Gynecologic Oncology
|
June 23, 2019
Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study
Rüdiger Klapdor, Linn Wölber, Lars Hanker, et al.
Gynecologic Oncology
|
November 7, 2017
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)
Felicia T Roncolato, Dominique Berton-Rigaud, Rachel O'Connell, et al.
Gynecologic Oncology
|
November 19, 2021
Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study
Linn Woelber, Katharina Prieske, Christine Zu Eulenburg, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
December 28, 2023
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7
Sabine Heublein, Jacobus Pfisterer, Andreas du Bois, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
March 1, 2019
Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions
Boris Winterhoff, Stefan Kommoss, Florian Heitz, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 107) with videos related to
Sort By:
Page
of 11
Gynecologic Oncology
|
March 15, 2024
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer
Paul Gass, Falk C Thiel, Lothar Häberle, et al.
International Journal of Surgery (London, England)
|
February 24, 2025
Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis
Fabian Trillsch, Bastian Czogalla, Sven Mahner, et al.
Annals of Surgical Oncology
|
March 16, 2021
Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study
Linn Woelber, Mareike Bommert, Philipp Harter, et al.
Gynecologic Oncology
|
February 15, 2019
Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study
Stephan Polterauer, Richard Schwameis, Christoph Grimm, et al.
The Oncologist
|
June 10, 2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
Felicia T Roncolato, Florence Joly, Rachel O'Connell, et al.
Gynecologic Oncology
|
June 23, 2019
Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study
Rüdiger Klapdor, Linn Wölber, Lars Hanker, et al.
Gynecologic Oncology
|
November 7, 2017
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)
Felicia T Roncolato, Dominique Berton-Rigaud, Rachel O'Connell, et al.
Gynecologic Oncology
|
November 19, 2021
Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study
Linn Woelber, Katharina Prieske, Christine Zu Eulenburg, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
December 28, 2023
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7
Sabine Heublein, Jacobus Pfisterer, Andreas du Bois, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
March 1, 2019
Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions
Boris Winterhoff, Stefan Kommoss, Florian Heitz, et al.
Page
of 11